SCHEMBL7524767

SCHEMBL7524767

Cc1ccc2ncnc(-c3ccc(C#N)cc3)c2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 5/20 0.54
MAPKAPK2 P49137 1/20 0.47
ALDH1A1 P00352 5/20 0.44
CYP1A2 P05177 3/20 0.44
CYP3A4 P08684 2/20 0.44
CLK4 Q9HAZ1 2/20 0.44
KDM4E B2RXH2 3/20 0.44
LMNA P02545 3/20 0.44
MAPK1 P28482 2/20 0.44
TP53 P04637 1/20 0.44
CYP2C9 P11712 1/20 0.44
HPGD P15428 1/20 0.44
TSHR P16473 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
HSD17B10 Q99714 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
CYP2A6 P11509 1/20 0.43
F9 P00740 1/20 0.43
GRM2 Q14416 1/20 0.41
EGLN2 Q96KS0 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13585391 0.80 ADORA2A (0.62) MAP4K4ALDH1A1CYP1A2CYP3A4KDM4E
SCHEMBL183242 0.79 PIK3CD (0.58) MAP4K4ALDH1A1CYP1A2CYP3A4CLK4
SCHEMBL182541 0.77 MAP4K4 (0.61) MAP4K4ALDH1A1CYP1A2CYP3A4CLK4
SCHEMBL7510851 0.76 MAP4K4 (0.44) MAP4K4MAPKAPK2ALDH1A1CYP1A2KDM4E
SCHEMBL14189311 0.76 MAP4K4 (0.68) MAP4K4MAPKAPK2ALDH1A1CYP1A2CYP3A4
SCHEMBL24795209 0.73 GRM5 (0.43) MAP4K4ALDH1A1CYP1A2CYP3A4CLK4
SCHEMBL22549000 0.71 IRAK4 (0.50) MAP4K4ALDH1A1CYP1A2CYP3A4CLK4
SCHEMBL6768273 0.71 GRM2 (0.53) MAPKAPK2ALDH1A1KDM4ELMNAHPGD
SCHEMBL15587280 0.70 MAP4K4 (1.00) MAP4K4
SCHEMBL12357140 0.69 ADORA2A (0.72) ALDH1A1KDM4EMAPK1SMN1; SMN2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0832073-B1 QUINAZOLINES AND PHARMACEUTICAL COMPOSITIONS SUGEN INC (US) 2002-01-16 EP disclosed
US-6103728-A MODULATING TYROSINE SIGNAL TRANSDUCTION TO PREVENT AND TREAT CELL PROLIFERATIVE DISORDERS OR CELL DIFFERENTIATION DISORDERS BY INHIBITING ONE OR MORE ABNORMAL TYROSINE KINASE ACTIVITIES; ANTICARCINOGENIC,-TUMOR, PROLIFERATIVE AGENTS SUGEN, INC. (US) 2000-08-15 US disclosed
EP-0832073-A1 QUINAZOLINES AND PHARMACEUTICAL COMPOSITIONS Sugen, Inc. (US) 1998-04-01 EP disclosed
WO-1996040648-A1 QUINAZOLINES AND PHARMACEUTICAL COMPOSITIONS SUGEN, INC. (US) 1996-12-19 WO disclosed